INmune Bio Announces Upcoming Video on MINDFuL Trial Results
INmune Bio Inc. (NASDAQ: INMB) is set to release an informative video that delves into the additional findings from the Phase 2 MINDFuL trial, which tests the efficacy of XPro™, a groundbreaking selective soluble TNF inhibitor.
A Glimpse into the Video Presentation
This upcoming video promises to provide viewers with an extensive overview of the significant clinical insights revealed at the Alzheimer’s Association International Conference (AAIC). The presentation will explore how XPro™ was assessed in the MINDFuL study and the implications of these findings for patients, clinicians, and investors keen on the advancements in Alzheimer’s disease treatment options.
The Significance of the MINDFuL Trial
The MINDFuL trial is a pivotal double-blind, Phase 2 proof-of-concept study focused on understanding the potential of XPro™ to combat cognitive decline in early-stage Alzheimer’s disease (AD). By addressing neuroinflammation, the trial has shown compelling changes in clinical indicators such as cognition, behavior, and AD-related biomarkers. These changes indicate a consistent benefit from treatment with XPro™ over a six-month period among a specific group of patients displaying amyloid-beta pathology and at least two blood biomarkers indicative of inflammation.
Expert Insights from INmune Bio
Dr. CJ Barnum, Vice President of CNS Drug Development at INmune Bio, expressed enthusiasm about the results derived from the trial. He stated, "The meaningful changes seen in a short trial are very encouraging. We are particularly excited that Dr. Sharon Cohen will present our findings at AAIC, and we look forward to sharing this valuable information broadly through our video format."
Availability of the Video
Mark your calendars! The informative video will be available at 4 PM ET on a Thursday in the near future, highlighting the rich information discussed during the AAIC session. Viewers interested in obtaining this wealth of knowledge can find it on INmune Bio’s YouTube Channel.
About INmune Bio Inc.
INmune Bio Inc. is a dynamic clinical-stage biotechnology company traded publicly on NASDAQ under the ticker INMB. The company is dedicated to innovating treatments that engage the innate immune system to combat various diseases. With three core product platforms, including a novel Dominant-Negative Tumor Necrosis Factor (DN-TNF) technology, INmune Bio is evaluating its potential for treating Mild Alzheimer’s disease, Mild Cognitive Impairment, and treatment-resistant depression with XPro™. In addition, their Natural Killer Cell Priming Platform aims to enhance the patient’s NK cell responses against cancer, currently undergoing trials in metastatic castration-resistant prostate cancer. The third platform, CORDStrom™, encompasses an allogeneic human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has shown promise in clinical settings.
Frequently Asked Questions
What is the focus of the MINDFuL trial?
The MINDFuL trial focuses on evaluating XPro™ as a treatment for slowing cognitive decline in patients with early-stage Alzheimer’s disease.
When will the video be available?
The video detailing the findings from the MINDFuL trial will be available on INmune Bio’s YouTube Channel at 4 PM ET on a Thursday following the conference.
What technology does INmune Bio utilize for its treatments?
INmune Bio employs Dominant-Negative Tumor Necrosis Factor (DN-TNF) technology to selectively neutralize soluble TNF, addressing immune dysfunction caused by chronic inflammation.
Who is leading the presentations at AAIC?
Dr. Sharon Cohen will present the data at the Alzheimer’s Association International Conference on behalf of INmune Bio.
How can I get in touch with INmune Bio?
You can reach INmune Bio by contacting David Moss, Chief Financial Officer, at (561) 710-0512 or via email at info@inmunebio.com.
